Literature DB >> 8563768

Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults.

H L McLeod1, E Y Krynetski, J A Wilimas, W E Evans.   

Abstract

Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of aromatic and heterocyclic sulfhydryl compounds, including thiopurine antimetabolites (i.e. mercaptopurine and thioguanine). The activity of TPMT in erythrocytes and other tissues exhibits genetic polymorphism, which is inherited as an autosomal codominant trait. Although inheritance is the principal determinant of TPMT activity, other factors (e.g. renal function, race and thiopurine therapy) have been shown to influence erythrocyte TPMT activity. Because the TPMT polymorphism has not been established in early erythrocyte populations, and the activity of many enzymes differs in neonates, we determined the activity of TPMT in erythrocytes obtained from 60 full-term newborns. Median peripheral blood TPMT activity was 25.3 U per ml pRBC (range 9-52.8 U per ml pRBC), which was > 50% higher than race matched healthy adults (p < 0.001). Western blot analysis demonstrated higher TPMT protein content in erythrocytes from newborns compared to adults, and revealed a significant correlation between TPMT protein and TPMT activity in erythrocytes (rs = 0.63, p = 0.03). Although erythrocyte TPMT activity was significantly higher in newborns, the distribution of activity in newborns was consistent with the genetic polymorphism previously observed in adults.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563768     DOI: 10.1097/00008571-199510000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  14 in total

Review 1.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 2.  Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.

Authors:  Tiphaine Adam de Beaumais; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-03-16       Impact factor: 2.953

Review 3.  Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.

Authors:  E Y Krynetski; W E Evans
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

4.  Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.

Authors:  Tiphaine Adam de Beaumais; May Fakhoury; Yves Medard; Said Azougagh; Daolun Zhang; Karima Yakouben; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

5.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

6.  Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.

Authors:  C Liu; W Yang; D Pei; C Cheng; C Smith; W Landier; L Hageman; Y Chen; J J Yang; K R Crews; N Kornegay; S E Karol; F L Wong; S Jeha; J T Sandlund; R C Ribeiro; J E Rubnitz; M L Metzger; C-H Pui; W E Evans; S Bhatia; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2016-11-18       Impact factor: 6.875

7.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

8.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

9.  Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age.

Authors:  Catherine Ganiere-Monteil; Yves Medard; Corinne Lejus; Béatrice Bruneau; Alain Pineau; Odile Fenneteau; Michel Bourin; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

10.  Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs.

Authors:  Barbara Wusk; G A Kullak-Ublick; C Rammert; A von Eckardstein; M Fried; K M Rentsch
Journal:  Eur J Clin Pharmacol       Date:  2004-02-24       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.